Systematic review and meta-analysis of MDMA-assisted therapy for trauma and depression

Photo by Logan Voss / Unsplash

medRxiv Published May 21, 2026 Medically reviewed May 21, 2026 Study authors: Borgogna, N. C.; Whittington, D. D.; Owen, T.; Petrovitch, D.; Vaughn, J.; Struble, C.; Pagano, L. A… DOI ↗ By Dr. Ji-eun Park, MD · Brain, Mind & Pain

Key Takeaway

Consider the potential of MDMA-assisted therapy for trauma, but note evidence gaps and the need for larger trials.

This is a systematic review and meta-analysis of MDMA-assisted therapy for mental illness, focusing on trauma and depression. The authors synthesized data from 295 participants, comparing MDMA-assisted therapy to control interventions including inert placebos and active controls.

The meta-analysis found a significant moderate-to-large incremental reduction in psychopathology relative to controls, with an effect size of g = 1.03 (95% CI [0.46, 1.60]). For trauma reduction, the effect was strong, with g = 1.46 (95% CI: 0.67, 2.25). Effects for depression were smaller and non-significant, with g = 0.51 (95% CI: -0.06, 1.08). Compared to inert placebos, effects were larger (g = 1.27), while effects versus active controls were smaller (g = 0.75).

The authors acknowledge limitations, including small samples, confounding factors, and mediocre harm reporting quality. Safety outcomes such as adverse events, serious adverse events, discontinuations, and tolerability were not reported.

The review concludes that MDMA-assisted therapy demonstrates potential transdiagnostic efficacy, but larger and more transparent clinical trials are needed to confirm findings and assess safety.

Study Details

Study typeSystematic review

Sample sizen = 295

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

Mental illness poses a substantial global burden, yet existing psychotherapies and psychopharmacologies often produce limited outcomes. Psychedelic assisted therapies have emerged as potential transdiagnostic interventions. In particular, 3,4 methylenedioxymethamphetamine assisted therapy (MDMA AT) has generated interest for its rapid psychological effects and potential to enhance psychotherapy outcomes. However, the incremental efficacy of MDMA AT relative to control interventions across transdiagnostic outcomes remains unclear. Further, there have been emerging concerns regarding harm reporting quality in MDMA AT clinical trials. We conducted a systematic review and meta analysis of MDMA AT randomized controlled trials. Eleven publications representing eight controlled trials with 10 analyzed subgroups (n = 295 participants) were included in meta-analyses. Two additional secondary publications were included for harm reporting syntheses (k = 13 total). Across 114 extracted effect sizes, MDMA AT demonstrated a significant moderate-to-large incremental reduction in psychopathology relative to controls (g = 1.03, 95% CI [0.46, 1.60]), though heterogeneity was high (I squared = 76%). Incremental effects were larger versus inert placebos (g = 1.27) than active controls (g = 0.75). Symptom specific analyses indicated strong incremental effects for trauma reduction (g=1.46 [95% CI: 0.67, 2.25]) and smaller non-significant effects for depression (g=0.51 [95% CI: -0.06, 1.08]). Harm reporting quality synthesis showed only 23% of publications met high-quality reporting standards. Overall, MDMA AT demonstrates potential transdiagnostic efficacy, but small samples, confounding factors, and mediocre harm reporting highlight the need for larger more transparent clinical trials.